Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
NCT04410965
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
82
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
TERIFLUNOMIDE
Sponsor
Sanofi